newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma Appoints Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer

  • Ascentage Pharma Group International appointed Faiçal Miyara, PhD, as Chief Business Officer to lead global business development.
  • Jim Ziegler was appointed as Chief Commercial Officer to oversee product commercialization in the United States and regions outside China.
  • Both executives will report directly to Chairman and CEO Dr. Dajun Yang.
  • Dr. Miyara brings over 20 years of oncology business development experience, including prior roles at IO Biotech, Ipsen, Pfizer, ImClone Systems, and Eli Lilly.
  • Mr. Ziegler has more than 25 years of commercial leadership experience from companies such as Amgen, Gilead Sciences, Iovance Biotherapeutics, and Geron.
  • Ascentage Pharma is advancing global registrational Phase III trials for olverembatinib (POLARIS-1, POLARIS-2, POLARIS-3) and lisaftoclax (GLORA, GLORA-2, GLORA-3, GLORA-4).
  • The company's first approved product, olverembatinib, is a third-generation BCR-ABL1 inhibitor approved in China for specific chronic myeloid leukemia populations.
  • The second approved product, lisaftoclax, is a Bcl-2 inhibitor approved in China for chronic lymphocytic leukemia/small lymphocytic lymphoma patients previously treated with BTK inhibitors.
  • The company maintains partnerships with major pharmaceutical firms including Takeda, AstraZeneca, Merck, Pfizer, and Innovent.